About Retatrutide (LY3437943)

Retatrutide (LY-3437943) is a triple agonist peptide of the GIP, GLP-1, and Glucagon receptors, representing a new class of multifunctional incretins under research. In Phase 2 clinical trials, it demonstrated a weight reduction of up to 24.2% over 48 weeks, with a half-life of approximately 6 days.

The triple mechanism of action involves:

• Activation of the GIP, promoting insulin sensitivity;
• Activation of the GLP-1, regulating insulin secretion and gastric emptying;
• Activation of the Glucagon, stimulating energy expenditure and hepatic lipolysis.

Main Research Areas

• Significant weight loss (up to 24–28% of body weight)
• Triple action on metabolic receptors
• Accelerated fat burning
• Potent appetite suppression
• Improvement of overall metabolic profile

Mechanism of Action

Simultaneous GLP-1R, GIPR, and GCGR agonism: GLP-1R enhances insulin secretion and reduces appetite; GIPR potentiates insulin and attenuates nausea; GCGR stimulates hepatic lipolysis, thermogenesis, and energy expenditure.

Purity ≥99% verified by HPLC. For research purposes only.

Purity: ≥99% by HPLC |  Form: Lyophilized Powder  |   Use: Research Use Only (RUO)

Legal Notice

This content is provided strictly for research purposes and does not constitute an endorsement or recommendation for non-laboratory use. The information is exclusively informational in nature and should not be interpreted as medical, clinical, or legal guidance. For Research Purposes Only.